Trial Profile
A study assessing one year outcomes after switching from a bivalirudin-first strategy to a heparin first strategy for all percutaneous coronary interventions in a single-center cardiac catheterization lab.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Oct 2016
Price :
$35
*
At a glance
- Drugs Bivalirudin (Primary) ; Heparin (Primary)
- Indications Acute coronary syndromes; Thrombosis
- Focus Adverse reactions; Therapeutic Use
- 08 Oct 2016 New trial record